Zevra Therapeutics, Inc. Research and Development Expense
Zevra Therapeutics, Inc. (ZVRA) reported Research and Development Expense of $3.08 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-05-12
- Zevra Therapeutics, Inc. research and development expense for the quarter ending 2022-03-31 was $3.08M, a 36.07% increase year-over-year.
- Zevra Therapeutics, Inc. research and development expense for the quarter ending 2021-12-31 was $2.81M, a 8.02% decline year-over-year.
- Zevra Therapeutics, Inc. research and development expense for the quarter ending 2021-09-30 was $2.24M, a 31.01% increase year-over-year.
- Zevra Therapeutics, Inc. research and development expense for the quarter ending 2021-06-30 was $2.85M, a 45.75% increase year-over-year.
- Zevra Therapeutics, Inc. research and development expense for fiscal 2021 was $10.16M, a 14.90% increase from fiscal 2020.
- Zevra Therapeutics, Inc. research and development expense for fiscal 2020 was $8.84M, a 54.45% decline from fiscal 2019.
- Zevra Therapeutics, Inc. research and development expense for fiscal 2019 was $19.41M, a 53.51% decline from fiscal 2018.
- Zevra Therapeutics, Inc. research and development expense for fiscal 2018 was $41.76M, a 102.78% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-03-31 | $3.08M 10-Q · filed 2022-05-12 | $5.89M derived: sum of 2 quarters · filed 2022-05-12 | $8.13M derived: sum of 3 quarters · filed 2022-05-12 | $10.98M derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $5.05M derived: sum of 2 quarters · filed 2022-03-31 | $7.90M derived: sum of 3 quarters · filed 2022-03-31 | $10.16M 10-K · filed 2022-03-31 |
| 2021-09-30 | $2.24M 10-Q · filed 2021-11-10 | $5.09M derived: sum of 2 quarters · filed 2021-11-10 | $7.35M 10-Q · filed 2021-11-10 | $10.41M derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-06-30 | $2.85M 10-Q · filed 2021-08-13 | $5.11M 10-Q · filed 2021-08-13 | $8.17M derived: sum of 3 quarters · filed 2022-05-12 | $9.88M derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-03-31 | $2.27M 10-Q · filed 2022-05-12 | $5.32M derived: sum of 2 quarters · filed 2022-05-12 | $7.03M derived: sum of 3 quarters · filed 2022-05-12 | $8.98M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $4.76M derived: sum of 2 quarters · filed 2022-03-31 | $6.72M derived: sum of 3 quarters · filed 2022-03-31 | $8.84M 10-K · filed 2022-03-31 |
| 2020-09-30 | $1.71M 10-Q · filed 2021-11-10 | $3.66M derived: sum of 2 quarters · filed 2021-11-10 | $5.79M 10-Q · filed 2021-11-10 | $8.25M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $1.95M 10-Q · filed 2021-08-13 | $4.08M 10-Q · filed 2021-08-13 | $6.54M derived: sum of 3 quarters · filed 2021-08-13 | $10.16M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $2.13M 10-Q · filed 2021-05-14 | $4.59M derived: sum of 2 quarters · filed 2021-05-14 | $8.21M derived: sum of 3 quarters · filed 2021-05-14 | $13.01M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $6.08M derived: sum of 2 quarters · filed 2021-03-12 | $10.88M derived: sum of 3 quarters · filed 2021-03-12 | $19.41M 10-K · filed 2021-03-12 |
| 2019-09-30 | $3.62M 10-Q · filed 2020-10-30 | $8.42M derived: sum of 2 quarters · filed 2020-10-30 | $16.95M 10-Q · filed 2020-10-30 | $23.25M derived: sum of 4 quarters · filed 2020-10-30 |
| 2019-06-30 | $4.80M 10-Q · filed 2020-08-12 | $13.33M 10-Q · filed 2020-08-12 | $19.64M derived: sum of 3 quarters · filed 2020-08-12 | $32.97M derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | $8.53M 10-Q · filed 2020-05-13 | $14.84M derived: sum of 2 quarters · filed 2020-05-13 | $28.16M derived: sum of 3 quarters · filed 2020-05-13 | $38.65M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $19.63M derived: sum of 2 quarters · filed 2020-02-28 | $30.12M derived: sum of 3 quarters · filed 2020-02-28 | $41.76M 10-K · filed 2020-02-28 |
| 2018-09-30 | $13.33M 10-Q · filed 2019-11-14 | $23.82M derived: sum of 2 quarters · filed 2019-11-14 | $35.45M 10-Q · filed 2019-11-14 | $40.99M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $10.49M 10-Q · filed 2019-08-13 | $22.13M 10-Q · filed 2019-08-13 | $27.66M derived: sum of 3 quarters · filed 2019-08-13 | $33.95M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $11.64M 10-Q · filed 2019-05-14 | $17.17M derived: sum of 2 quarters · filed 2019-05-14 | $23.47M derived: sum of 3 quarters · filed 2019-05-14 | $28.12M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | $5.54M 10-K · filed 2018-03-30 | $11.83M derived: sum of 2 quarters · filed 2018-11-09 | $16.48M derived: sum of 3 quarters · filed 2018-11-09 | $20.59M 10-K · filed 2019-03-01 |
| 2017-09-30 | $6.29M 10-Q · filed 2018-11-09 | $10.94M derived: sum of 2 quarters · filed 2018-11-09 | $15.06M 10-Q · filed 2018-11-09 | $23.02M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $4.65M 10-Q · filed 2018-08-10 | $8.76M 10-Q · filed 2018-08-10 | $16.73M derived: sum of 3 quarters · filed 2018-08-10 | $21.01M derived: sum of 4 quarters · filed 2018-08-10 |
| 2017-03-31 | $4.11M 10-Q · filed 2018-05-11 | $12.08M derived: sum of 2 quarters · filed 2018-05-11 | $16.36M derived: sum of 3 quarters · filed 2018-05-11 | $21.35M derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $7.96M 10-K · filed 2018-03-30 | $12.25M derived: sum of 2 quarters · filed 2018-03-30 | $17.24M derived: sum of 3 quarters · filed 2018-03-30 | $20.47M 10-K · filed 2018-03-30 |
| 2016-09-30 | $4.29M 10-K · filed 2018-03-30 | $9.28M derived: sum of 2 quarters · filed 2018-03-30 | $12.51M 10-Q · filed 2017-11-09 | $17.23M derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-06-30 | $4.99M 10-K · filed 2018-03-30 | $8.22M 10-Q · filed 2017-08-10 | $12.94M derived: sum of 3 quarters · filed 2018-03-30 | $17.27M derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-03-31 | $3.23M 10-K · filed 2018-03-30 | $7.95M derived: sum of 2 quarters · filed 2018-03-30 | $12.28M derived: sum of 3 quarters · filed 2018-03-30 | $15.05M derived: sum of 4 quarters · filed 2018-03-30 |
| 2015-12-31 | $4.72M 10-K · filed 2017-03-10 | $9.04M derived: sum of 2 quarters · filed 2017-03-10 | $11.81M derived: sum of 3 quarters · filed 2017-03-10 | $13.93M 10-K · filed 2018-03-30 |
| 2015-09-30 | $4.33M 10-K · filed 2017-03-10 | $7.10M derived: sum of 2 quarters · filed 2017-03-10 | $9.21M 10-Q · filed 2016-11-10 | $15.13M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $2.77M 10-K · filed 2017-03-10 | $4.89M 10-Q · filed 2016-08-11 | $10.80M derived: sum of 3 quarters · filed 2017-03-10 | $14.05M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $2.12M 10-K · filed 2017-03-10 | $8.03M derived: sum of 2 quarters · filed 2017-03-10 | $11.28M derived: sum of 3 quarters · filed 2017-03-10 | $13.00M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | $5.91M 10-K · filed 2016-03-16 | $9.16M derived: sum of 2 quarters · filed 2016-03-16 | $10.88M derived: sum of 3 quarters · filed 2016-03-16 | $11.92M 10-K · filed 2017-03-10 |
| 2014-09-30 | $3.25M 10-K · filed 2016-03-16 | $4.97M derived: sum of 2 quarters · filed 2016-03-16 | $6.01M 10-Q · filed 2015-11-13 | |
| 2014-06-30 | $1.72M 10-K · filed 2016-03-16 | $2.75M 10-Q · filed 2015-08-14 | ||
| 2014-03-31 | $1.04M 10-K · filed 2016-03-16 | |||
| 2013-12-31 | $3.37M 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |